All In Biotech

Drug Trial Radar · NCT06116253

Advanced Diffusion Imaging in Renal Cancer Patients

Advanced Diffusion Imaging in Renal Cancer Patients: Oncologic Control and Renal Functional Reserve

Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

39

Actual

Start

Dec 1, 2022

Primary completion

Dec 1, 2028

Study completion Dec 1, 2028

Sponsor

Lead sponsor
NYU Langone HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institutes of Health (NIH)
First posted
Nov 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 21 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to apply advanced diffusion imaging in a two-pronged assessment of renal mass patients: (1) characterization of lesion malignancy and subtype, and (2) prediction of renal function stability or decline following partial nephrectomy.

Conditions

  • Renal Cancer

Interventions

  • Magnetic Resonance Imaging (MRI) ScanDevice

    Participants will undergo a 1-hour research MRI scan.

  • Tc-99m PentetateDrug

    Participants will receive radioisotope (99mTc-DTPA) injection (5 mCi) during 3-5 hour scanning session to estimate measured glomerular filtration rate (mGFR).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Times Lesion Type is Correctly Predicted using IVIM-MRI at Pre-SurgeryTime frame: Baseline (1 Week Prior to Operation)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • NYU Langone Health

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.